Oxipit vs Qure AI (2026)
The furthest point on the autonomy axis against the broadest regulatory footprint. Oxipit holds the only approval anywhere for autonomous diagnostic reporting, certified in Europe to identify high confidence normal chest radiographs and issue finalised reports with no radiologist involved, and the regulatory bar forced it to publish operating characteristics most vendors never disclose. Qure triages and flags across nine products with the widest chest radiograph regulatory footprint in the market, and the radiologist reads every study. For a European service drowning in normal films, Oxipit removes them from the queue entirely, which nothing else can do. The condition is permanent: its false negative rate at the operating threshold has to be monitored locally forever, because nobody will ever catch the miss.
- It is the only regulatory approved application performing diagnostic reporting autonomously, holding certification to identify high confidence normal chest radiographs and issue finalised reports with no radiologist involved.
- The regulatory bar forced disclosure most vendors never face, and the company published the operating characteristics behind it.
- For a service whose backlog is normal chest films, removing them from the worklist entirely is a structural saving rather than an incremental one.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products with published device dossiers.
- It is deployed where reading capacity is thinnest, including public health screening programmes, which is a harder operating environment than a hospital worklist.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Oxipit and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Oxipit its top capability grade on AI Centrality and Model and Technology Transparency. Set against Qure AI, Oxipit grades higher on HIPAA and BAA Posture, EHR and Interoperability Depth and Commercial Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Qure AI its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Oxipit, Qure AI grades higher on several axes, including Clinical and Operational Evidence, Security Certifications and Trust Center and FDA and Regulatory Status. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Oxipit or Qure AI?
On the axes where the AI Health Index separates them, Oxipit grades higher on HIPAA and BAA Posture, EHR and Interoperability Depth and Commercial Transparency, and Qure AI grades higher on several axes, including Clinical and Operational Evidence, Security Certifications and Trust Center and FDA and Regulatory Status. Qure AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Oxipit and Qure AI differ most?
The widest separation the AI Health Index records between Oxipit and Qure AI is on Setting and Specialty Coverage, where Oxipit grades C and Qure AI grades A. That axis sits in the Commercial group, so it should carry the most weight for a buyer whose binding constraint is contracting, scope and what the price actually covers.
Where do Oxipit and Qure AI grade the same?
The AI Health Index grades Oxipit and Qure AI the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
This is the sharpest autonomy comparison in imaging and the evidence bars are not the same. An application that issues a finalised report needs its false negative rate at the operating threshold published and revalidated locally, because a missed finding on an autonomously reported film is seen by nobody, ever, while a triage product leaves the radiologist reading every study.
Oxipit's certification is European and does not transfer to other jurisdictions, and its acquisition raises questions about which entity holds the certification and the security posture. Neither publishes pricing.